Medpace Forecast, price target & analysts
Medpace Target price 2025 - Analyst rating & recommendation
Medpace Classifications & Recommendation:
Medpace Price Target
| Target Price | $356.75 |
| Price | $326.11 |
| Potential |
9.40%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Medpace 2026 .
The average Medpace target price is $356.75.
This is
9.40%
register free of charge
$404.00
23.88%
register free of charge
$300.00
8.01%
register free of charge
|
|
| A rating was issued by 12 analysts: 4 Analysts recommend Medpace to buy, 7 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medpace stock has an average upside potential 2026 of
9.40%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 2.11 | 2.17 |
| 11.84% | 2.74% | |
| EBITDA Margin | 22.58% | 22.04% |
| 17.23% | 2.37% | |
| Net Margin | 18.30% | 17.40% |
| 27.18% | 4.92% |
9 Analysts have issued a sales forecast Medpace 2025 . The average Medpace sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an Medpace EBITDA forecast 2025. The average Medpace EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Medpace Analysts have issued a net profit forecast 2025. The average Medpace net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 12.63 | 12.34 |
| 42.23% | 2.30% | |
| P/E | 26.44 | |
| EV/Sales | 4.35 |
8 Analysts have issued a Medpace forecast for earnings per share. The average Medpace <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Medpace stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Current Medpace Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Baird | Locked ➜ Locked | Locked | Jan 27 2025 |
| Baird | Locked ➜ Locked | Locked | Nov 25 2024 |
| Baird | Locked ➜ Locked | Locked | Oct 23 2024 |
| TD Cowen | Locked ➜ Locked | Locked | Oct 23 2024 |
| William Blair | Locked ➜ Locked | Locked | Oct 22 2024 |
| Redburn Atlantic | Locked ➜ Locked | Locked | Oct 14 2024 |
| Truist Securities | Locked ➜ Locked | Locked | Oct 14 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Baird: Locked ➜ Locked
|
Jan 27 2025 |
|
Locked
Baird: Locked ➜ Locked
|
Nov 25 2024 |
|
Locked
Baird: Locked ➜ Locked
|
Oct 23 2024 |
|
Locked
TD Cowen: Locked ➜ Locked
|
Oct 23 2024 |
|
Locked
William Blair: Locked ➜ Locked
|
Oct 22 2024 |
|
Locked
Redburn Atlantic: Locked ➜ Locked
|
Oct 14 2024 |
|
Locked
Truist Securities: Locked ➜ Locked
|
Oct 14 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
